Standard BioTools Inc. (FLDM) Stock Analysis

Standard BioTools Inc. (FLDM) Healthcare & Pipeline Overview

Standard BioTools Inc. provides innovative tools for life science research, including analytical and preparatory systems, integrated fluidic circuits, and software solutions. With a focus on genomics, proteomics, and cell biology, the company serves academic, clinical, and biopharmaceutical sectors, holding a strategic position in the diagnostics and research industry.

What Is the Investment Thesis for FLDM?

With a market capitalization of $294M and a P/E ratio of 5.06, the company demonstrates strong profitability, indicated by a profit margin of 119.1%. Key value drivers include the increasing demand for single-cell analysis and high-throughput screening technologies. Growth catalysts include expansion into new geographic markets and continued innovation in its product offerings. However, investors should be aware of potential risks such as competition from larger players and regulatory hurdles. The company's gross margin of 51.9% reflects its ability to maintain pricing power and manage costs effectively.

Based on FMP financials and quantitative analysis

FLDM Key Highlights

Market Cap of $294M indicates the company's current valuation in the market.

• P/E ratio of 5.06 suggests the company may be undervalued compared to its earnings.
• Profit Margin of 119.1% highlights the company's strong profitability and efficient operations.
• Gross Margin of 51.9% demonstrates the company's ability to maintain pricing power and manage production costs effectively.
• Beta of 1.14 indicates the stock's volatility is slightly higher than the market average.

Who Are FLDM's Competitors?

FLDM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FLDM's Key Strengths?

Innovative product portfolio in high-growth areas.

• Strong gross profit margin.
• Established customer base in academic and clinical markets.
• Proprietary technology in microfluidics.

What Are FLDM's Weaknesses?

Relatively small market capitalization compared to competitors.

• Dependence on research and development spending trends.
• Limited geographic diversification.
• Competition from larger, more established players.

What Could Drive FLDM Stock Higher?

Launch of new assays and reagents for emerging research areas.

• Expansion into new geographic markets, particularly in Asia-Pacific.
• Strategic partnerships with leading research institutions and pharmaceutical companies.
• Increasing adoption of single-cell analysis technologies.

What Are the Key Risks for FLDM?

Financial-distress signal — its Altman Z-Score of 0.01 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-18.2%) — the business is not currently generating profit on shareholder capital.
• Competition from established players with greater resources.
• Regulatory hurdles and compliance requirements.
• Technological obsolescence.
• Economic downturns affecting research funding.

What Are the Growth Opportunities for FLDM?

• Expansion into Emerging Markets: Standard BioTools has the opportunity to expand its presence in emerging markets such as Asia-Pacific and Latin America, where the demand for advanced research tools is growing rapidly. These regions offer significant growth potential due to increasing investments in healthcare and research infrastructure. Successfully penetrating these markets could significantly boost revenue and market share. The market size for research tools in Asia-Pacific is projected to reach $XX billion by 2028, presenting a substantial opportunity for Standard BioTools.
• Development of New Assays and Reagents: The company can drive growth by developing new assays and reagents that cater to emerging research areas such as immuno-oncology and personalized medicine. By expanding its product portfolio, Standard BioTools can attract new customers and increase sales to existing customers. The market for immuno-oncology assays is expected to reach $YY billion by 2027, offering a significant growth opportunity.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with leading research institutions and pharmaceutical companies can accelerate the development and commercialization of new products. Collaborations can provide access to valuable resources, expertise, and distribution channels, enhancing the company's competitive position. Collaborating with pharmaceutical companies on drug discovery and development projects can create new revenue streams and strengthen the company's brand.
• Increased Adoption of Single-Cell Analysis: The increasing adoption of single-cell analysis technologies in research and clinical applications presents a significant growth opportunity for Standard BioTools. The company's C1 systems and IFCs are well-positioned to capitalize on this trend. The market for single-cell analysis is projected to reach $ZZ billion by 2026, driven by the growing demand for personalized medicine and precision diagnostics.
• Enhancement of Software Solutions: Standard BioTools can enhance its software solutions to provide more comprehensive data analysis and visualization capabilities. By improving the user experience and adding new features, the company can attract more customers and increase customer loyalty. Investing in software development can also create new revenue opportunities through the sale of software licenses and subscriptions. Enhanced software solutions can also improve the efficiency and productivity of researchers and clinicians, further driving adoption of Standard BioTools' products.

What Are FLDM's Competitive Advantages?

• Proprietary technology in integrated fluidic circuits and single-cell microfluidics.
• Strong brand reputation and established customer base.
• Extensive patent portfolio protecting its key technologies.
• Strategic partnerships with leading research institutions.

What Does FLDM Do?

Standard BioTools Inc., formerly known as Fluidigm Corporation, was founded in 1999 and is headquartered in South San Francisco, California. The company creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Its product portfolio includes analytical systems like the Helios CyTOF system and Hyperion imaging systems, as well as preparatory instruments such as Juno systems and Biomark HD systems. These systems are complemented by a range of assays and reagents, including Maxpar reagents, Advanta RNA-Seq NGS library prep kits, and Advanta Dx SARS-CoV-2 RT-PCR assays. The company also offers integrated fluidic circuits (IFCs) and single-cell microfluidics solutions. Standard BioTools serves a diverse customer base, including academic research institutions, translational research centers, cancer centers, clinical research laboratories, biopharmaceutical companies, and contract research organizations. Through license agreements with institutions like the California Institute of Technology and Harvard University, Standard BioTools continues to innovate and expand its offerings in the life sciences sector. The company's evolution reflects a commitment to providing cutting-edge tools that enable advancements in genomics, proteomics, and cell biology.

What Products and Services Does FLDM Offer?

• Develops and manufactures analytical systems for life science research.
• Offers preparatory instruments for sample preparation.
• Provides integrated fluidic circuits (IFCs) for various applications.
• Creates and markets assays and reagents for genomic and proteomic analysis.
• Offers single-cell microfluidics solutions.
• Develops software solutions for data analysis and visualization.
• Markets products to academic, clinical, and biopharmaceutical customers.

How Does FLDM Make Money?

• Sells instruments and systems to research and clinical laboratories.
• Generates recurring revenue through the sale of consumables and reagents.
• Provides software licenses and subscriptions for data analysis.
• Offers service and support contracts for its instruments.

What Industry Does FLDM Operate In?

Standard BioTools Inc. operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The market is driven by factors such as the growing prevalence of chronic diseases, the increasing adoption of molecular diagnostics, and the rising investments in research and development. The competitive landscape includes established players like Thermo Fisher Scientific and Danaher, as well as emerging companies focused on innovative technologies. Standard BioTools differentiates itself through its integrated fluidic circuits and single-cell microfluidics solutions, catering to the specific needs of researchers and clinical laboratories.

Who Are FLDM's Key Customers?

• Academic research institutions
• Translational research and medicine centers
• Cancer centers
• Clinical research laboratories
• Biopharmaceutical and biotechnology companies

Standard BioTools Inc. Financial Trajectory

Standard BioTools Inc. (FLDM) reported $20.1M in revenue for Q2 FY2026, a decline of 4.9% compared to the prior quarter. The company recorded a net loss of $26.8M, with diluted EPS of $-68.46. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, FLDM averaged $-17.04 in diluted EPS.

Company Profile

Standard BioTools Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Stephen Linthwaite. FLDM has traded publicly since 2011.

How Standard BioTools Inc. Is Valued

Standard BioTools Inc. carries a market capitalization of $294M, placing it in the micro-cap category.

Return on equity for Standard BioTools Inc. stands at -18.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -32.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -34.4%, the inverse of the P/E and a quick read on earnings relative to price.

Standard BioTools Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.01 places it in the distress zone, a signal of elevated financial risk.

Standard BioTools Inc. has beaten Wall Street's EPS estimate in 4 of its last 7 reported quarters — more hits than misses. Reported results have landed about 26.5% below estimates on average.

The most recent 12 insider filings for Standard BioTools Inc. break down as 7 sales and 5 purchases. On net that is roughly 11K shares disposed (about $115K), a signal worth weighing alongside the fundamentals.

FLDM Financials

FLDM Latest News

What Investors Ask About Standard BioTools Inc. (FLDM) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources